Ani Pharmaceuticals (ANIP) Long-Term Debt Repayments (2022 - 2024)
Historic Long-Term Debt Repayments for Ani Pharmaceuticals (ANIP) over the last 3 years, with Q3 2024 value amounting to $291.0 million.
- Ani Pharmaceuticals' Long-Term Debt Repayments rose 1950000.0% to $291.0 million in Q3 2024 from the same period last year, while for Sep 2024 it was $295.5 million, marking a year-over-year increase of 3930000.0%. This contributed to the annual value of $3.0 million for FY2023, which is 0.0% changed from last year.
- Ani Pharmaceuticals' Long-Term Debt Repayments amounted to $291.0 million in Q3 2024, which was up 1950000.0% from $750000.0 recorded in Q2 2024.
- Ani Pharmaceuticals' Long-Term Debt Repayments' 5-year high stood at $291.0 million during Q3 2024, with a 5-year trough of -$1.5 million in Q3 2023.
- Over the past 3 years, Ani Pharmaceuticals' median Long-Term Debt Repayments value was $750000.0 (recorded in 2022), while the average stood at $27.1 million.
- Its Long-Term Debt Repayments has fluctuated over the past 5 years, first tumbled by 30000.0% in 2023, then skyrocketed by 1950000.0% in 2024.
- Quarter analysis of 3 years shows Ani Pharmaceuticals' Long-Term Debt Repayments stood at $750000.0 in 2022, then skyrocketed by 300.0% to $3.0 million in 2023, then surged by 9600.0% to $291.0 million in 2024.
- Its last three reported values are $291.0 million in Q3 2024, $750000.0 for Q2 2024, and $750000.0 during Q1 2024.